Anticoagulants Market Size, Share & Trends Report

Anticoagulants Market Size, Share & Trends Analysis Report By Route of Administration (Oral Anticoagulants, Injectable Anticoagulants), By Drug Category, By Application (Atrial fibrillation, Pulmonary embolism), By Region, And Segment Forecasts, 2024 - 2030

Report ID: GVR-4-68040-191-0
Number of Pages: 125
Format: Electronic (PDF)

Historical Range: 2018 - 2022
Industry: Healthcare

Market Segmentation

Anticoagulants Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
- Novel oral anticoagulants (NOACs)
  - Eliquis
  - Xarelto
  - Savaysa & Lixiana
  - Pradaxa
- Heparin and Low Molecular Weight Heparin (LMWH)
- Vitamin k Antagonist
- Direct thrombin inhibitors
- Others
Anticoagulants Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
- Oral anticoagulants
- Injectable anticoagulants
Anticoagulants Application Outlook (Revenue in USD Million; 2018 - 2030)
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism
- Other Applications
Anticoagulants Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
    - Novel Oral Anticoagulants (NOACs)
      - Eliquis
      - Xarelto
      - Savaysa & Lixiana
      - Pradaxa
    - Heparin and Low Molecular Weight Heparin (LMWH)
    - Vitamin k antagonist
    - Direct thrombin inhibitors
    - Others
  - North America Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
    - Oral anticoagulants
    - Injectable anticoagulants
  - North America Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Atrial fibrillation/myocardial infarction (heart attack)
    - Deep Vein Thrombosis (DVT)
    - Pulmonary embolism
    - Other
  - U.S.
    - U.S. Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - U.S. Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - U.S. Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - Canada
    - Canada Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Canada Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Canada Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
- Europe
  - Europe Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
    - Novel Oral Anticoagulants (NOACs)
      - Eliquis
      - Xarelto
      - Savaysa & Lixiana
      - Pradaxa
    - Heparin and Low Molecular Weight Heparin (LMWH)
    - Vitamin k antagonist
    - Direct thrombin inhibitors
    - Others
  - Europe Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
    - Oral anticoagulants
    - Injectable anticoagulants
  - Europe Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Atrial fibrillation/myocardial infarction (heart attack)
    - Deep Vein Thrombosis (DVT)
    - Pulmonary embolism
    - Other
  - Germany
    - Germany Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Germany Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Germany Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - UK
    - UK Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - UK Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - UK Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - France
    - France Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - France Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - France Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - Italy
    - Italy Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Italy Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Italy Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - Spain
    - Spain Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Spain Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Spain Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - Denmark
    - Denmark Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Denmark Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Denmark Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - Sweden
    - Sweden Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Sweden Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Sweden Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - Norway
    - Norway Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Norway Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Norway Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
- Asia Pacific
  - Asia Pacific Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
    - Novel Oral Anticoagulants (NOACs)
      - Eliquis
      - Xarelto
      - Savaysa & Lixiana
      - Pradaxa
    - Heparin and Low Molecular Weight Heparin (LMWH)
    - Vitamin k antagonist
    - Direct thrombin inhibitors
    - Others
  - Asia Pacific Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
    - Oral anticoagulants
    - Injectable anticoagulants
  - Asia Pacific Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Atrial fibrillation/myocardial infarction (heart attack)
    - Deep Vein Thrombosis (DVT)
    - Pulmonary embolism
    - Other
  - China
    - China Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - China Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - China Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - Japan
    - Japan Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Japan Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Japan Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - India
    - India Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - India Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - India Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - South Korea
    - South Korea Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - South Korea Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - South Korea Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - Australia
    - Australia Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Australia Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Australia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - Thailand
    - Thailand Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Thailand Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Thailand Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
- Latin America
  - Latin America Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
    - Novel Oral Anticoagulants (NOACs)
      - Eliquis
      - Xarelto
      - Savaysa & Lixiana
      - Pradaxa
    - Heparin and Low Molecular Weight Heparin (LMWH)
    - Vitamin k antagonist
    - Direct thrombin inhibitors
    - Others
  - Latin America Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
    - Oral anticoagulants
    - Injectable anticoagulants
  - Latin America Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Atrial fibrillation/myocardial infarction (heart attack)
    - Deep Vein Thrombosis (DVT)
    - Pulmonary embolism
    - Other
  - Brazil
    - Brazil Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Brazil Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Brazil Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - Mexico
    - Mexico Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Mexico Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Mexico Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - Argentina
    - Argentina Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Argentina Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Argentina Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
- Middle East Africa
  - Middle East Africa Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
    - Novel Oral Anticoagulants (NOACs)
      - Eliquis
      - Xarelto
      - Savaysa & Lixiana
      - Pradaxa
    - Heparin and Low Molecular Weight Heparin (LMWH)
    - Vitamin k antagonist
    - Direct thrombin inhibitors
    - Others
  - Middle East Africa Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
    - Oral anticoagulants
    - Injectable anticoagulants
  - Middle East Africa Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Atrial fibrillation/myocardial infarction (heart attack)
    - Deep Vein Thrombosis (DVT)
    - Pulmonary embolism
    - Other
  - South Africa
    - South Africa Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - South Africa Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - South Africa Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - Saudi Arabia
    - Saudi Arabia Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Saudi Arabia Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Saudi Arabia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - UAE
    - UAE Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - UAE Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - UAE Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others
  - Kuwait
    - Kuwait Drug Category Outlook (Revenue in USD Million, 2018 - 2030)
      - Novel Oral Anticoagulants (NOACs)
        
        Eliquis
        
        Xarelto
        
        Savaysa & Lixiana
        
        Pradaxa
      - Heparin and Low Molecular Weight Heparin (LMWH)
      - Vitamin k Antagonist
      - Direct thrombin inhibitors
      - Others
    - Kuwait Route of Administration Outlook (Revenue in USD Million, 2018 - 2030)
      - Oral anticoagulants
      - Injectable anticoagulants
    - Kuwait Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Atrial fibrillation/myocardial infarction (heart attack)
      - Deep Vein Thrombosis (DVT)
      - Pulmonary embolism
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.